바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

악성 흉막액에서 CEA와 CYFRA 21-1의 진단적 유용성

Diagnostic Utility of Pleural Fluid CEA and CYFRA 21-1 for Malignant Pleural Effusions

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2004, v.57 no.1, pp.32-36
정재호 (관동대학교)
최정은 (관동대학교)
김성규 (연세대학교)
박무석 (연세대학교)
김영삼 (연세대학교)
장준 (연세대학교)
김세규 (연세대학교)
김주항 (연세대학교)
황상연 (연세대학교)
문진욱 (연세대학교)
  • 다운로드 수
  • 조회수

Abstract

Background:The purpose of this study was to evaluate the usefulness of the pleural fluid carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) tumor markers as complementary tools for the diagnosis of malignant pleural effusions.Patients and Methods:The levels of pleural and serum CEA and CYFRA 21-1 were prospectively assayed in 222 patients with pleural effusions (150 benign effusions, 57 bronchogenic carcinomas and 15 metastatic carcinomas).Results:The levels of pleural fluid CEA and CYFRA 21-1 in the malignant effusions were significantly higher than those in the benign effusions. With a specificity of 95%, the cut off values for the CEA and CYFRA 21-1 in pleural effusions were 5 and 89 ng/ml, respectively. The diagnostic sensitivities of the pleural fluid CEA and CYFRA 21-1 in malignant effusions were 72 and 54%, respectively, whereas using a combination of the two, the sensitivity increased to 87% (p<0.05).Conclusions : These findings suggest that a combination of the pleural fluid CEA and CYFRA 21-1 in pleural effusions can be useful in the diagnosis of malignant pleural effusions.(Tuberc Respir Dis 2004; 57:32-36)

keywords
CEA, CYFRA 21-1, Malignant pleural effusions.

참고문헌

1.

(1985) Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion:analysis of 414 cases,

2.

(1997) Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions,

3.

(1993) CYFRA 21-1.A new marker in lung cancer,

4.

a sensitive and specific new tumour marker for squamous cell lung cancer Report of the first European multicentre evaluation,

5.

(chest1980) agnostic value of carcinoembryonic antigen in exuꠀ,

6.

(1988) Tumor markers in pleural effusion diagnosis,

7.

(1996) Assessment of serum CYFRA 21-1 in lung cancer,

8.

(1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer,

9.

(1996) Evaluation of CYFRA 21-1 in malignant and benign pleural effusions,

10.

(1995) Clinical evaluation of CYFRA 21-1 in malignant pleural fluids,

11.

(1999) Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level deterꠀminations in the serum and pleural fluid of patients with pleural effusions,

12.

(1999) Diagnostic value of CYFRA 21-1 in diffeꠀrential diagnosis of pleural effusion,

13.

(1993) Clinical significance of the combined assay of pleural fluid ADA activity and CEA level in the various pleural effusions,

14.

(1998) Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions,

15.

(2001) Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma,

16.

(1996) CEA,CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions,

17.

(2001) Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions,

Tuberculosis & Respiratory Diseases